EUCTR2011-000460-10-ES
进行中（未招募）
1 期
First year growth response associated geneticmarkers validation Phase IV open-label study inGrowth Hormone Deficient and Turner Syndromepre-pubertal children : the PREDICTPharmacogenetics Validation Study - PREDICT PGx Validation Study
Merck Serono S.A. Geneva0 个研究点目标入组 461 人2011年6月21日
概览
- 阶段
- 1 期
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- Merck Serono S.A. Geneva
- 入组人数
- 461
- 状态
- 进行中（未招募）
- 最后更新
- 4年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Pre\-established diagnosis of IGHD or TS based on classical criteria
- •with at least 1 year of r\-hGH therapy and with Tanner stage 1 at
- •treatment start
- •Retrospective availability of a complete set of clinical, auxological
- •and biological parameters necessary for building the predictive
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 350
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 45
- •F.1\.3 Elderly (\>\=65 years) no
排除标准
- •Acquired GHD
- •Any drug or disease that could affect growth
结局指标
主要结局
未指定
相似试验
进行中（未招募）
不适用
Validation study for genetic markers for growth hormone treatment in growth hormone deficient and turner syndrome patientsEUCTR2011-000460-10-GBMerck Serono SA395
进行中（未招募）
不适用
Validation study for genetic markers for growth hormone treatment in growth hormone deficient and turner syndrome patientsIdiopathic Growth Hormone Deficiency and Turner SyndromeMedDRA version: 13.1Level: PTClassification code 10056438Term: Growth hormone deficiencySystem Organ Class: 10014698 - Endocrine disordersMedDRA version: 13.1Level: PTClassification code 10045181Term: Turner's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Body processes [G] - Metabolic Phenomena [G03]EUCTR2011-000460-10-CZMerck Serono S.A. Geneva395
进行中（未招募）
不适用
Validation study for genetic markers for growth hormone treatment in growth hormone deficient and turner syndrome patientsEUCTR2011-000460-10-ITMERCK SERONO SA395
已完成
3 期
Sub-study on genetic markers responsible to effects of HMG-CoA reductase inhibitor preventing recurrence of strokeIschemic strokeJPRN-UMIN000008055Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences1,000
招募中
不适用
Investigation of biomarkers related to growth hormone administratioJPRN-jRCTs031230066Furihata Kenichi5